Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
reALiSe: Phase 2a study of ARGX-119 in ALS
2024-511318-19-00Phase 2Completed
- Sponsor
- argenx
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing ARGX-119 with Placebo (2 arms). Primary endpoints: Assessment of adverse events (AEs) and Assessment of clinical laboratory tests, ECGs and vital signs. Started Sep 2024; status: completed.
02
Drugs
adimanebart
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2024-511318-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511318-19-00.